Maxx's Top Stock for June 2021 - 7investing 7investing
Stock Tips Mobile Menu Dropdown Icon

Maxx’s Top Stock for June 2021

7investing Lead Advisor Maxx Chatsko's Top Stock for June 2021 is well positioned to build solutions for some of the biggest obstacles facing the genetic testing markets.

June 1, 2021

Advisor: Maxx Chatsko

Genetic testing still sucks. Doctors rarely consider a genetic test as a first-line diagnostic. Prices are high and quality is low. There’s little guidance or know-how for interpreting molecular information to benefit patients through lifestyle changes or treatment optimization.

7investing Lead Advisor Maxx Chatsko’s recommendation for June 2021 is well-positioned to build solutions for some of the biggest obstacles facing the molecular testing markets.


A drug developer that’s well-positioned to deliver on the promises of genetic medicines.

Hey everyone, I’m 7investing Lead Advisor Maxx Chatsko. Here at 7investing we empower you to invest in your future by giving you our seven best stock market opportunities each and every month, each backed by the domain competence of one of our lead advisors.

My recommendation for April 2021 is a very high risk investment, but primarily due to development risks, not valuation risks, which is important in the current market. In fact, I think this might be one of the most undervalued drug developers on the stock market.

Investors have heard all about CRISPR gene editing and there’s a lot of excitement for the approach. However, it’s interesting to me that scientists tend to have many more reservations. Many wonder if we rushed the tool into clinical trials without fully understanding the risks. I tend to agree with that perspective. This actually highlights an important reality for investors: There are over one dozen genetic medicine tools. Each adds value in specific applications, and no tool can do it all.

My recommendation is developing a next-generation technology platform that addresses some of the core obstacles encountered by all genetic medicines. The pipeline is buzzing with activity, investors can expect two to three clinical assets to be added to the pipeline each year for the foreseeable future. The approach is known to be safe and effective, while assets tend to have high rates of success if the proper genetic targets are selected. In fact, its first drug candidate could be approved and readying for this launch by this time next year.

If you want to know more about this company and the technology it’s developing, please go to to read my full research report. We are 7investing, and we’re here to help empower you to invest in your future.